Key clinical point: Tirofiban was far more effective than cangrelor at achieving rapid and potent inhibition of platelet aggregation in patients undergoing primary percutaneous coronary intervention for ST-elevation MI.
Major finding: Thirty minutes after administration, tirofiban-treated ST-elevation MI patients had 95% platelet inhibition in vitro, compared with 34.1% with cangrelor, 10.5% with chewed prasugrel, and 6.3% with prasugrel swallowed whole.
Study details: This was a randomized, open-label, multinational clinical trial including 122 patients undergoing primary percutaneous coronary intervention for ST-elevation MI.
Disclosures: The presenter reported that Medicure, the sponsor of the FABOLUS FASTER trial, provided an institutional research grant to conduct the study.
Valgimigli M. EuroPCR 2020.